Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

'A Lot of Action' in The Development of Targeted Therapies for Mantle Cell Lymphoma

May 22nd 2020, 10:00pm

Video

Evidence shows that Bruton’s tyrosine kinase inhibitors, one of many targeted therapies, are highly effective in patients with mantle cell lymphoma.

CAR T-Cell Therapy a 'Really Exciting' Development in Treatment of Lymphomas

May 21st 2020, 5:00pm

Video

The evolution of CAR T-cell therapy has been an exciting development for the treatment of all lymphomas, including mantle cell lymphoma, according to Dr. Ian Flinn.

Attacking the 'Achilles Heel' of Aggressive Lymphomas

May 18th 2020, 10:25pm

Article

Precision medicine is improving outcomes for aggressive types of lymphomas, such as mantle cell lymphoma.

In Mantle Cell Lymphoma, Velcade After Stem Cell Transplant Delays Disease Progression

May 16th 2020, 1:00am

Article

Velcade not only delays the progression of mantle cell lymphoma when given after stem cell transplant but also prolongs survival. However, the treatment comes with significant side effects.

High-Dose Chemotherapy Regimen Shows Good Response in Certain Patients with Mantle Cell Lymphoma

April 7th 2020, 5:00pm

Article

Patients with mantle cell lymphoma who were eligible for stem cell transplant saw a 97% overall response rate to a three-drug regimen, according to findings from two clinical trials.

CAR-T Cell Therapy Shows Promise in Patients with Mantle Cell Lymphoma

April 6th 2020, 5:00pm

Article

At one-year follow-up, phase 2 clinical trial results showed that most patients with relapsed or treatment resistant mantle cell lymphoma responded to chimeric antigen receptor (CAR)-T cell therapy.

Speaking Out: Treatment Options May Expand in Mantle Cell Lymphoma

March 5th 2020, 3:00am

Article

An expert sheds light on the latest therapies in clinical trials and promising drug combinations to thwart the aggressive disease.

BTK Inhibitors Offer Improved Response Over Chemotherapy in Mantle Cell Lymphoma

February 28th 2020, 1:00am

Article

Patients with relapsed/refractory mantle cell lymphoma saw more favorable responses with the BTK inhibitor Imbruvica (ibrutinib) than with chemotherapy, according to nearly a decade of data.

Immune-Based Therapies Emerge in Mantle Cell Lymphoma

February 24th 2020, 7:19pm

Article

Patients with the aggressive blood cancer can turn to immunotherapies like CAR-T cell therapy when disease recurs or becomes resistant.

FDA Grants Priority Review to CAR-T Cell Therapy for Mantle Cell Lymphoma

February 11th 2020, 7:00pm

Article

The Food and Drug Administration granted a priority review to KTE-X19 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.